Results

1–10 of 14 results for Zone

The Effect of Baseline Ellipsoid Zone-Area Loss on Treatment Response of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2
Sophie Jane Bakri, MD
Annual Meeting Talks
2025
Ellipsoid Zone Integrity Preservation and Characterization of Ellipsoid Zone Integrity Features in the GATHER 1 Phase 2/3 Study
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2023
Evaluation of EZ At-Risk Burden in Automatic Detection of Hydroxychloroquine Retinopathy
Katherine E Talcott, MD
Annual Meeting Talks
2023
Comparison of Complete vs Incomplete Closure of Zone 3 Scleral Lacerations
Pedro S Tetelbom, MD
Annual Meeting Talks
2023
Use of Ellipsoid Zone Analysis As an Efficacy Endpoint in Clinical Trials for Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2023
Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study
Glenn J. Jaffe, MD
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024
Modeling Zone as a Proxy for Absolute Avascular Retina Area and Retinopathy of Prematurity Risk
Darius M. Moshfeghi, MD, FASRS
Annual Meeting Talks
2022